Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.

@article{Linch2008ExperienceIA,
  title={Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.},
  author={Mark Linch and F Stavridi and Jane Hook and Yolanda Barbachano and Martin Gore and Stanley B. Kaye},
  journal={Gynecologic oncology},
  year={2008},
  volume={109 1},
  pages={
          27-32
        }
}
OBJECTIVES Weekly paclitaxel (WP) has been reported to have significant activity in patients with ovarian and primary peritoneal cancer patients while retaining a favorable toxicity profile. This study assessed the current usage of WP in routine clinical practice in a tertiary cancer center. METHODS We conducted a retrospective audit in 53 patients with recurrent ovarian or primary peritoneal cancer treated with WP (80-100 mg/m(2)) over a 2-year period (Nov 2003-Nov 2005). Toxicity was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Current treatment and clinical trials in ovarian cancer.

Expert opinion on investigational drugs • 2010
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Novel therapeutic agents in ovarian cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology • 2006
View 2 Excerpts
Highly Influenced

Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2003
View 3 Excerpts
Highly Influenced

The effect of single weekly paclitaxel in heavily pretreated ovarian cancer patients and its antiangiogenic effects

KKY Kudoh, T Kita
Proc Am Soc Clin Oncol 2005:5115 • 2005

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2005
View 1 Excerpt